Steatohepatitis/Metabolic Liver Disease

You have full text access to this OnlineOpen article

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†

  1. Luca Miele1,
  2. Venanzio Valenza2,‡,
  3. Giuseppe La Torre3,‡,
  4. Massimo Montalto1,‡,
  5. Giovanni Cammarota1,
  6. Riccardo Ricci4,
  7. Roberta Mascianà1,
  8. Alessandra Forgione1,
  9. Maria L. Gabrieli1,
  10. Germano Perotti2,
  11. Fabio M. Vecchio4,
  12. Gianlodovico Rapaccini1,
  13. Giovanni Gasbarrini1,
  14. Chris P. Day5,§,
  15. Antonio Grieco1,§,¶,*

Article first published online: 23 JAN 2009

DOI: 10.1002/hep.22848

Issue

Hepatology

Hepatology

Volume 49, Issue 6, pages 1877–1887, June 2009

Additional Information

How to Cite

Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., Vecchio, F. M., Rapaccini, G., Gasbarrini, G., Day, C. P. and Grieco, A. (2009), Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 49: 1877–1887. doi: 10.1002/hep.22848

Author Information

  1. 1

    Institute of Internal Medicine, Catholic University of Rome, Rome, Italy

  2. 2

    Institute of Nuclear Medicine, Catholic University of Rome, Rome, Italy

  3. 3

    Institute of Public Health—Biostatistic Unit, Catholic University of Rome, Rome, Italy

  4. 4

    Institute of Pathology, Catholic University of Rome, Rome, Italy

  5. 5

    Institute of Cellular Medicine, University of Newcastle, Newcastle upon Tyne, UK

  1. ‡

    These authors contributed equally to this work.

  2. §

    These authors share senior authorship.

  3. fax: (39)-(0)6-35502775.

*Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia “Agostino Gemelli” Istituto di Medicina Interna, Largo Agostino Gemelli 8 - 00168 Rome, Italy

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 23 JAN 2009
  3. Accepted manuscript online: 23 JAN 2009 12:00AM EST
  4. Manuscript Accepted: 13 JAN 2009
  5. Manuscript Received: 16 SEP 2008

Funded by

  • Cofin MIUR - Università Cattolica del Sacro Cuore. Grant Number: “Linea D.1” 2004
  • Cofin MIUR, Università Cattolica del Sacro Cuore and “Istituto Toniolo Research Prize”. Grant Number: “Giovani Ricercatori” 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1034K)

References

  • 1
    Clark JM, Brancati F, Diehl AM. Prevalence of nonalcoholic fatty liver disease in the general population of the United States. Am J Gastroenterol 2003; 98: 960–967.
    Direct Link:
  • 2
    Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 282–291.e1.
  • 3
    Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006; 26: 1021–1028.
    Direct Link:
  • 4
    Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557–2562.
  • 5
    Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006; 103: 12511–12516.
  • 6
    Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206–211.
  • 7
    Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531–537.
  • 8
    Benoni C, Prytz H. Effects of smoking on the urine excretion of oral 51Cr-EDTA in ulcerative colitis. Gut 1998; 42; 656–658.
  • 9
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on dectection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
  • 10
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
  • 11
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network: design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313–1321.
    Direct Link:
  • 12
    National Institutes of Health. Consensus Development Conference Statement on Celiac Disease. June 28-30, 2004. http://consensus.nih.gov/2004/2004CeliacDisease118main.htm. Accessed January 2009.
  • 13
    Cammarota G, Cesaro P, La Mura R, Martino A, Cazzato A, Miele L, et al. Role of the “immersion technique” in diagnosing celiac disease with villous atrophy limited to the duodenal bulb. J Clin Gastroenterol 2007; 41: 571–575.
  • 14
    Rossi M, Sganga G, Mazzone M, Valenza V, Guarneri S, Portale G, et al. Cardiopulmonary bypass in man: role of the intestine in a self-limiting inflammatory response with demonstrable bacterial translocation. Ann Thorac Surg 2004; 77: 612–618.
  • 15
    Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 21: 1391–1395.
    Direct Link:
  • 16
    Montalto M, Cuoco L, Ricci R, Maggiano N, Vecchio FM, Gasbarrini G. Immunohistochemical analysis of ZO-1 in duodenal mucosa of patients with untreated and treated celiac disease. Digestion 2002; 65: 227–233.
  • 17
    Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K. The G.U.T. of gut. Scand J Gastroenterol 2004; 39: 807–815.
  • 18
    Zeuzem S. Gut-liver axis. Int J Colorectal Dis 2000; 15: 59–82.
  • 19
    Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681–687.
  • 20
    Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008; 28: 1026–1033.
    Direct Link:
  • 21
    DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385–396.
  • 22
    Arslan G, Atasever T, Cindoruk M, Yildirim IS. 51CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. Nucl Med Commun 2001; 22: 997–1001.
  • 23
    Bjarnason I, Ward K, Peters TJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984; 28: 179–182.
  • 24
    Zuckerman MJ, Watts MT, Bhatt BD, Ho H. Intestinal permeability to 51CrEDTA in infectious diarrhea. Dig Dis Sci 1993; 38: 1651–1657.
  • 25
    Cobden I, Rothwell J, Axon ATR. Intestinal permeability and screening tests for coeliac disease. Gut 1980; 21: 512–518.
  • 26
    Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, et al. The diagnosis of small bowel bacterial overgrowth: reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 302–309.
  • 27
    Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95: 982–928.
  • 28
    Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852–858.
  • 29
    Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 1200–1204.
    Direct Link:
  • 30
    Jacob AI, Goldberg PK, Bloom N, Degenstein GA, Kozinn PJ. Endotoxin and bacteria in portal blood. Gastroenterology 1977; 72: 1268–1270.
  • 31
    Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821–830.
  • 32
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature 2006; 444: 1022–1023.
  • 33
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–1031.
  • 34
    Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palu G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518–G525.
  • 35
    Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986; 103: 755–766.
  • 36
    Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, et al. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004; 69: 225–228.
  • 37
    Gottardi CJ, Arpin M, Fanning AS, Louvard D. The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. Proc Natl Acad Sci U S A 1996; 93: 10779–10784.
  • 38
    Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002; 49: 1582–1586.
  • 39
    Soza A, Riquelme A, Gonzalez R, Alvarez M, Perez-Ayuso RM, Glasinovic JC, et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 1136–1140.
  • 40
    Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–1772.
  • 41
    Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983–992.
  • 42
    Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452–1455.
  • 43
    Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. HEPATOLOGY 2003; 37: 909–916.
    Direct Link:
  • 44
    Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993–999.
  • 45
    Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740–E747.
  • 46
    Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser BA, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003; 37: 343–350.
    Direct Link:
View Full Article (HTML) Get PDF (1034K)